NCT00750555View on ClinicalTrials.gov

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Head and Neck Cancer

Interventions

DRUG

Erlotinib

150 mg per day orally until disease progression occurs, up to a maximum of 12 months

Trial Locations (1)

17822

Geisinger Health System, Danville

Sponsors

Lead Sponsor

Geisinger Clinic

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Geisinger Clinic

OTHER